Technical Analysis for GH - Guardant Health, Inc.

Grade Last Price % Change Price Change
grade D 74.73 -0.33% -0.25
GH closed down 0.33 percent on Tuesday, September 17, 2019, on 1.76 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Earnings due: Sep 27

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical GH trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -0.33%
Oversold Stochastic Weakness -0.33%
Inside Day Range Contraction -3.57%
Wide Bands Range Expansion -3.57%
Oversold Stochastic Weakness -3.57%
New Downtrend Bearish -3.01%
Inside Day Range Contraction -3.01%

Older signals for GH ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. Its Guardant Health Oncology Platform is designed to leverage its capabilities in technology, clinical development, regulatory and reimbursement to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs. In pursuit of its goal to manage cancer across all stages of the disease, Guardant Health has launched multiple liquid biopsy-based tests, Guardant360 and GuardantOMNI, for advanced stage cancer patients, which fuel its development programs for recurrence and early detection, LUNAR-1 and LUNAR-2, respectively. Since its launch in 2014, Guardant360 has been used by more than 5,000 oncologists, over 40 biopharmaceutical companies and all 27 of the National Comprehensive Cancer Network centers.
Medicine Biopharmaceutical Cancer Medical Specialties Disease Oncology Precision Medicine
Is GH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 3 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 112.21
52 Week Low 27.04
Average Volume 1,037,529
200-Day Moving Average 70.1447
50-Day Moving Average 91.7164
20-Day Moving Average 86.596
10-Day Moving Average 78.813
Average True Range 4.5267
ADX 30.36
+DI 10.1762
-DI 30.705
Chandelier Exit (Long, 3 ATRs ) 92.2599
Chandelier Exit (Short, 3 ATRs ) 87.5801
Upper Bollinger Band 104.7556
Lower Bollinger Band 68.4364
Percent B (%b) 0.17
BandWidth 41.940967
MACD Line -5.3148
MACD Signal Line -4.0418
MACD Histogram -1.273
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 78.09
Resistance 3 (R3) 78.22 77.23 77.53
Resistance 2 (R2) 77.23 76.37 77.17 77.34
Resistance 1 (R1) 75.98 75.85 75.49 75.85 77.16
Pivot Point 74.99 74.99 74.74 74.93 74.99
Support 1 (S1) 73.74 74.13 73.25 73.61 72.30
Support 2 (S2) 72.75 73.61 72.69 72.12
Support 3 (S3) 71.50 72.75 71.93
Support 4 (S4) 71.37